Drugs / VNX001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06394830 | Dec 2024 → Jun 2026 overdue | interstitial cystitis | Vaneltix Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05737121 | May 2023 → Jun 2026 overdue | interstitial cystitis | Vaneltix Pharma, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNX001 | “VNX001 (alkalinized lidocaine HCl and heparin sodium)” NCT05737121 ↗ |
| Route | Other | “administered as a single dose via intravesical instillation” NCT05737121 ↗ |